Pulmonary Arterial Hypertension

Why trials studying Pulmonary Arterial Hypertension stopped, in this sample of ClinicalTrials.gov.

18 stopped trials with a clear reason; 78% ended for non-scientific reasons.

Trials

• Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin
  NCT05060315 · TERMINATED · funding or business
  “Sponsor Decision”
• A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
  NCT04791514 · TERMINATED · slow enrollment
  “Low enrolment”
• miRNA and Myokines in Patients With PAH
  NCT03905083 · WITHDRAWN · staffing, sites or logistics
  “Logistics related to research activity”
• Olaparib for PAH: a Multicenter Clinical Trial
  NCT03782818 · TERMINATED · funding or business
  “The recruitment was stopped on October 31st 2024 due to limited recruitment within the last year, as well as the end of funding (Spring 2025).”
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
  NCT03657095 · TERMINATED · futility
  “The pivotal study, BPS-314d-MR-PAH-302 (NCT01908699), failed to demonstrate efficacy.”
• Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
  NCT02999906 · WITHDRAWN · funding or business
  “For business reasons.”
• Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
  NCT02927366 · TERMINATED · funding or business
  “Study was terminated early for strategic reasons. Only Part I of the study was completed.”
• Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
  NCT03016468 · WITHDRAWN · funding or business
  “Business decision”
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
  NCT02725372 · TERMINATED · futility
  “Trial stopped for futility”
• Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide
  NCT02436512 · WITHDRAWN · slow enrollment
  “Inability meet enrollment in study population.”
• A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH
  NCT02284737 · TERMINATED · slow enrollment
  “Lack of subjects.”
• FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
  NCT02958358 · WITHDRAWN · slow enrollment
  “inability to recruit subjects”
• Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease
  NCT01319045 · TERMINATED · slow enrollment
  “enrollment was too slow”
• Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
  NCT00795639 · TERMINATED · safety
  “Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.”
• Iloprost Power Disc-15 in Pulmonary Arterial Hypertension
  NCT00723554 · TERMINATED · funding or business
  “sponsor's decision”
• To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
  NCT00430716 · TERMINATED · funding or business
  “This study was terminated at the recommendation of an independent Data Monitoring Committee. The decision was not based on any safety concerns.”
• Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
  NCT00722254 · TERMINATED · slow enrollment
  “This study was stopped due to poor enrollment numbers”
• A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients With Pulmonary Arterial Hypertension
  NCT00811018 · TERMINATED · safety
  “This trial was prematurely terminated on Dec 9 2010 due to safety concerns, specifically emerging evidence of hepatic injury.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.